| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia (NCT04435691) | M.D. Anderson Cancer Center | 2020-07-28 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (NCT04293562) | Children's Oncology Group | 2020-07-21 |
| PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02390635) | M.D. Anderson Cancer Center | 2020-07-15 |
| LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy (NCT04081259) | Dana-Farber Cancer Institute | 2020-07-15 |
| Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen (NCT04219163) | Baylor College of Medicine | 2020-07-09 |
| Quality of Life Model for Older Patients With AML (NCT04380441) | H. Lee Moffitt Cancer Center and Research Institute | 2020-07-08 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation (NCT04464889) | Medigene AG | 2020-07-02 |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant (NCT03964506) | Omar Aljitawi | 2020-07-01 |
| A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (NCT05933070) | Inmune Bio, Inc. | 2020-06-15 |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) (NCT04155580) | Astex Pharmaceuticals, Inc. | 2020-06-12 |
| Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML (NCT04002115) | Milton S. Hershey Medical Center | 2020-06-03 |
| Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations (NCT04906031) | First Affiliated Hospital of Jinan University | 2020-06-01 |
| Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia (NCT04415008) | Institute of Hematology & Blood Diseases Hospital, China | 2020-06-01 |
| Outcomes of Acute Myeloid Leukemia Patients (NCT04392310) | Assiut University | 2020-06-01 |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (NCT04128748) | M.D. Anderson Cancer Center | 2020-05-27 |
| CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients (NCT04195945) | Fred Hutchinson Cancer Center | 2020-05-27 |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (NCT04256317) | Taiho Oncology, Inc. | 2020-05-21 |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia (NCT04188405) | M.D. Anderson Cancer Center | 2020-05-17 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting (NCT04128501) | M.D. Anderson Cancer Center | 2020-05-05 |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory (NCT03969446) | City of Hope Medical Center | 2020-05-04 |
| Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study. (NCT04311060) | Mexican Agrupation for Hematology Study | 2020-03-22 |
| Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia (NCT04774744) | M.D. Anderson Cancer Center | 2020-03-17 |
| Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia (NCT04277442) | National Cancer Institute (NCI) | 2020-03-11 |
| CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML (NCT04151706) | Robert Lowsky | 2020-02-27 |
| CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression (NCT04257175) | Sheba Medical Center | 2020-02-18 |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS (NCT04055844) | Masonic Cancer Center, University of Minnesota | 2020-02-17 |
| Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening (NCT04267081) | Helsinki University Central Hospital | 2020-02-12 |
| A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS (NCT04044209) | Yale University | 2020-02-12 |
| Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia (NCT04262843) | City of Hope Medical Center | 2020-02-07 |
| Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide (NCT03533816) | University of Kansas Medical Center | 2020-01-31 |
| A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (NCT04100330) | AVEO Pharmaceuticals, Inc. | 2020-01-31 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (NCT03934372) | Incyte Biosciences International Sàrl | 2020-01-29 |
| AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration (NCT04263181) | Washington University School of Medicine | 2020-01-29 |
| AflacLL1901 (CHOA-AML) (NCT04326439) | Emory University | 2020-01-24 |
| Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS (NCT04166929) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2020-01-15 |
| Venetoclax and Lintuzumab-Ac225 in AML Patients (NCT03867682) | Actinium Pharmaceuticals | 2020-01-15 |
| A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04243785) | Edgewood Oncology Inc. | 2020-01-06 |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia (NCT04215822) | Assiut University | 2020-01-01 |
| Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT04373395) | Zhejiang University | 2020-01-01 |
| Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia (NCT04910698) | Poitiers University Hospital | 2020-01-01 |
| Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease (NCT04209712) | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | 2020-01-01 |
| Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia (NCT04296214) | Grupo Cooperativo de Hemopatías Malignas | 2020-01-01 |
| Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML (NCT05982756) | Zhongnan Hospital | 2020-01-01 |
| Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia (NCT03374332) | Brown University | 2019-12-31 |
| A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment (NCT04112589) | PETHEMA Foundation | 2019-12-26 |
| A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (NCT04027309) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2019-12-20 |
| Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT (NCT03066466) | Loyola University | 2019-12-10 |
| TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia (NCT04692948) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-12-09 |
| Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT (NCT04476199) | Gruppo Italiano Trapianto di Midollo Osseo | 2019-12-09 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (NCT03836209) | PrECOG, LLC. | 2019-12-06 |
| GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia (NCT04051996) | Yale University | 2019-12-06 |
| Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML (NCT04248595) | Ge Zheng | 2019-12-01 |
| Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04060277) | City of Hope Medical Center | 2019-11-27 |
| Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (NCT04167696) | Celyad Oncology SA | 2019-11-25 |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT04013685) | Orca Biosystems, Inc. | 2019-11-21 |
| Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia (NCT03844815) | University of Chicago | 2019-11-18 |
| Randomized Clinical Study Assessing Haplo vs. URD in AML (NCT04067180) | Karolinska Institutet | 2019-11-12 |
| IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (NCT04086264) | AbbVie | 2019-11-06 |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (NCT04065399) | Syndax Pharmaceuticals | 2019-11-05 |
| AML Expressive Writing (NCT04006496) | Duke University | 2019-11-04 |
| A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers (NCT05541224) | PETHEMA Foundation | 2019-11-01 |
| D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients (NCT04168138) | Huihan Wang | 2019-11-01 |
| TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (NCT04173585) | University Hospital Heidelberg | 2019-10-22 |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT04047641) | M.D. Anderson Cancer Center | 2019-10-22 |
| A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML (NCT04038437) | Jazz Pharmaceuticals | 2019-10-15 |
| A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (NCT03922477) | Hoffmann-La Roche | 2019-10-08 |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) (NCT04093570) | Taiho Oncology, Inc. | 2019-09-30 |
| AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission (NCT04062266) | M.D. Anderson Cancer Center | 2019-09-13 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (NCT04067336) | Kura Oncology, Inc. | 2019-09-12 |
| Combining Active and Passive DNA Hypomethylation (NCT03999723) | Kirsten Grønbæk | 2019-09-11 |
| A Study of FMT in Patients With AML Allo HSCT in Recipients (NCT03678493) | Masonic Cancer Center, University of Minnesota | 2019-09-09 |
| Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 (NCT04070768) | John Quigley | 2019-09-06 |
| Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) (NCT04107727) | PETHEMA Foundation | 2019-09-05 |
| RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome (NCT04021368) | Ryvu Therapeutics SA | 2019-09-04 |
| Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics (NCT03897127) | University of Ulm | 2019-09-04 |
| IA14 Induction in Young Acute Myeloid Leukemia (NCT04069208) | Peking Union Medical College Hospital | 2019-09-03 |
| Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia (NCT04008381) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-09-01 |
| ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT04013880) | Vanderbilt-Ingram Cancer Center | 2019-08-27 |
| Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma (NCT04097301) | AGC Biologics S.p.A. | 2019-08-27 |
| Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2 (NCT04070807) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2019-08-23 |
| MRD-guided Treatment in NPM1mut AML Patients (NCT03769532) | Technische Universität Dresden | 2019-08-21 |
| Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results (NCT04060485) | National Taiwan University Hospital | 2019-08-19 |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (NCT04068597) | CellCentric Ltd. | 2019-08-09 |
| A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) (NCT03987958) | AbbVie | 2019-08-08 |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (NCT03860844) | Sanofi | 2019-08-06 |
| Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia (NCT03187691) | Matinas BioPharma Nanotechnologies, Inc. | 2019-08-01 |
| ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant (NCT03932643) | University of Nebraska | 2019-07-30 |
| Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia (NCT03789981) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2019-07-19 |
| Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation (NCT03728335) | City of Hope Medical Center | 2019-07-11 |
| AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells (NCT04169022) | Centre Hospitalier Universitaire de Besancon | 2019-07-10 |
| MIF Involvement in AML (NCT03918655) | Assistance Publique - Hôpitaux de Paris | 2019-07-07 |
| A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients (NCT04015024) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2019-07-01 |
| Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies (NCT03955783) | Sanjay Mohan | 2019-06-21 |
| Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT (NCT04173533) | University of Birmingham | 2019-06-14 |
| Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) (NCT03904134) | Center for International Blood and Marrow Transplant Research | 2019-06-14 |
| Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia (NCT03844997) | Sudipto Mukherjee, MD, PhD, MPH | 2019-06-06 |
| PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS (NCT03927261) | Precigen, Inc | 2019-05-20 |
| Long-term Outcomes for Acute Myeloid Leukemia Patients (NCT03755856) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2019-05-16 |
| IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome (NCT03503409) | Groupe Francophone des Myelodysplasies | 2019-05-14 |